Related Experiment Video
Updated: Jul 17, 2025
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Comparison of MiraLAX and magnesium citrate for bowel preparation at CT colonography
Nicholas Zacharias1, Meghan G Lubner1, David H Kim1
1Department of Radiology, University of Wisconsin School of Medicine & Public Health, E3/311 Clinical Science Center, 600 Highland Ave., Madison, WI, 53792-3252, USA.
Purpose:
To compare MiraLAX, a hypo-osmotic lavage, and magnesium citrate (MgC), a hyper-osmotic agent for bowel preparation at CTC.
Methods:
398 total screening CTC studies were included in this retrospective, single institution study. 297 underwent preparation with a double-dose MgC regimen (mean age, 61 ± 5.5 years; 142 male/155 female) and 101 with 8.3 oz (equivalent to 238 g PEG) of MiraLAX (mean age, 60 ± 9.6 years; 45 male/56 female). Oral contrast for tagging purposes was utilized in both regimens. Studies were retrospectively analyzed for residual fluid volume and attenuation by automated analysis, as well for subjective oral contrast coating of the normal colonic wall and polyps. 50 patients underwent successive CTC studies utilizing each agent (mean, 6.1 ± 1.7 years apart), allowing for intra-patient comparison. Chi-squared, Fisher's exact, McNemar, and t-tests were used for data comparison.
Results:
Residual fluid volume (as percentage of total colonic volume) and fluid density was 7.2 ± 4.2% and 713 ± 183 HU for the MgC cohort and 8.7 ± 3.8% and 1044 HU ± 274 for the MiraLAX cohort, respectively (p = 0.001 and p < 0.001, respectively). Similar results were observed for the intra-patient cohort. Colonic wall coating negatively influencing interpretation was noted in 1.7% of MgC vs. 6.9% of MiraLAX examinations (p = 0.008). Polyps were detected in 12% of all MgC vs. 16% of all MiraLAX CTCs (p = 0.29).
Conclusion:
CTC bowel preparation with the hypo-osmotic MiraLAX agent appears to provide acceptable diagnostic quality that is comparable to the hyper-osmotic MgC agent, especially when factoring in patient safety and tolerance.
Insights
MiraLAX bowel preparation for CT colonography (CTC) offers diagnostic quality comparable to magnesium citrate (MgC). This hypo-osmotic agent is a viable alternative, especially considering patient safety and tolerance in CTC procedures.
Area of Science:
- Gastroenterology
- Radiology
- Medical Imaging
Background:
- Effective bowel preparation is crucial for diagnostic quality in CT colonography (CTC).
- Both hypo-osmotic (MiraLAX) and hyper-osmotic (magnesium citrate, MgC) agents are used for bowel cleansing.
- Comparing the efficacy and safety of different bowel preparation agents is essential for optimizing CTC procedures.
Purpose of the Study:
- To compare the efficacy of MiraLAX (hypo-osmotic) versus magnesium citrate (MgC, hyper-osmotic) for bowel preparation in CTC.
- To evaluate residual fluid volume, attenuation, and colonic wall coating for both agents.
- To assess polyp detection rates and diagnostic quality between the two bowel preparation methods.
Main Methods:
- A retrospective study of 398 screening CTC examinations.
- Patients received either a double-dose MgC regimen (297 studies) or MiraLAX (101 studies).
- Automated analysis assessed residual fluid and attenuation; subjective assessment evaluated colonic wall coating and polyp visualization. Intra-patient comparisons were also performed.
Main Results:
- MiraLAX showed a trend towards higher residual fluid volume (8.7% vs 7.2%) and significantly higher fluid density (1044 HU vs 713 HU) compared to MgC (p < 0.001).
- Colonic wall coating negatively impacting interpretation was more frequent with MiraLAX (6.9% vs 1.7%, p=0.008).
- No significant difference in polyp detection rates was observed between MgC and MiraLAX (12% vs 16%, p=0.29).
Conclusions:
- CTC bowel preparation with MiraLAX provides acceptable diagnostic quality comparable to MgC.
- MiraLAX may be a suitable alternative, particularly when considering patient safety and tolerance.
- Further research may explore optimizing MiraLAX regimens for improved cleansing efficacy.
Related Concept Videos
01:26Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
01:23Lower GI Series: Barium Enema
Procedure Details
The examination begins by inserting a lubricated rectal tube into the patient's rectum to administer a radiopaque barium solution. The barium flow is carefully...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:14Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...